Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Minimising recurrence by using most effective treatment

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.05.12
Views: 3017
Rating:

Prof Fabrice Andre – Institut Gustave Roussy, Paris, France

Prof Fabrice Andre talks to ecancer about identifying patients with a high risk of recurrence at IMPAKT 2012 in Brussels, May 2012.

 

The importance of identifying high risk patients is not just discovering which are the most susceptible to relapse, but to avoid giving a patient a therapy that will have a low effect as well.

 

Prof Andre notes that by using protein based and prognostic biomarkers, the best possible therapy with the lowest risk of relapse, can be identified.

 

The second challenge that Prof Andre addresses is how to bridge the gap between research settings and clinical practice.

 

Filming Supported by Amgen

 

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation